Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine

Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine

Paltusotine is a nonpeptide selective somatostatin receptor 2 agonist in development as once-daily oral treatment for acromegaly. To evaluate the efficacy and safety of paltusotine in the treatment of patients with acromegaly previously controlled with injected somatostatin receptor ligands (SRLs)....

Full description

Saved in:
Bibliographic Details
Main Authors: Mônica R. Gadelha, Alessandra Casagrande, Christian J. Strasburger, Martin Bidlingmaier, Peter J. Snyder, Mirtha Guitelman, César Luiz Boguszewski, Michael Buchfelder, Ilan Shimon, Gérald Raverot, Miklós Tóth, Emese Mezősi, Mirjana Doknić, Xiaolin Fan, David R. Clemmons, Peter Trainer, R. Scott Struthers, Alan Krasner, Beverly M. K. Biller
Format: Artigo
Language:English
Published: 2024
Online Access:https://doi.org/10.1210/clinem/dgae385
https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgae385/58057980/dgae385.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1210/clinem/dgae385
https://academic.oup.com/jcem/advance-article-pdf/doi/10.1210/clinem/dgae385/58057980/dgae385.pdf

Similar Items